28 October 2020

Moderna has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a rolling review of the company’s mRNA-1273 vaccine to fight Covid-19. The announcement was made after receiving positive results from a preclinical mRNA-1273 viral challenge and the interim analysis of the Phase I study of the vaccine.

Olatec Therapeutics announced that it has enrolled it first patients into a Phase II clinical trial of the orally administered Dapansutrile capsules for treating patients with moderate Covid-19 symptoms and for evidence of early cytokine release syndrome. The trial aims to evaluate the safety and efficacy of Dapansutrile in 80 patients from various demographics.

Histogen and Amerimmune have collaborated to develop an orally active caspase inhibitor, Emricasan, to treat Covid-19. The US Food and Drug Administration (FDA) has also granted Investigational New Drug (IND) approval to Histogen to commence its Phase I study of Emricasan among mild Covid-19 patients to assess its safety and use.

Italy’s medicines regulator has approved human clinical trials for the osteoporosis drug, raloxifene to reduce Covid-19 symptoms, thereby making patients less infectious. Researchers are hoping that raloxifene will block virus replication in cells and thus slow the progress of the disease. Researchers used supercomputers to investigate approximately 400,000 molecules and more for chemical characteristics that might slow down the virus.